These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

412 related items for PubMed ID: 23391500

  • 1. Multiparameter analysis of serum levels of C-telopeptide crosslaps, bone-specific alkaline phosphatase, cathepsin K, osteoprotegerin and receptor activator of nuclear factor κB ligand in the diagnosis of osteoporosis.
    Piatek S, Adolf D, Wex T, Halangk W, Klose S, Westphal S, Amthauer H, Winckler S.
    Maturitas; 2013 Apr; 74(4):363-8. PubMed ID: 23391500
    [Abstract] [Full Text] [Related]

  • 2. Serum cathepsin K levels are not suitable to differentiate women with chronic bone disorders such as osteopenia and osteoporosis from healthy pre- and postmenopausal women.
    Adolf D, Wex T, Jahn O, Riebau C, Halangk W, Klose S, Westphal S, Amthauer H, Winckler S, Piatek S.
    Maturitas; 2012 Feb; 71(2):169-72. PubMed ID: 22197348
    [Abstract] [Full Text] [Related]

  • 3. Implications of measuring soluble receptor activators of nuclear factor-kappaB ligand and osteoprotegerin in bone metabolism of elderly women.
    Chiba Y, Onouchi T, Ikeda T, Adachi J, Tamura Y, Horiuchi T.
    Gerontology; 2009 Feb; 55(3):275-80. PubMed ID: 19158438
    [Abstract] [Full Text] [Related]

  • 4. Receptor activator of NF(Kappa)B ligand/osteoprotegerin (RANKL/OPG) system and osteopontin (OPN) serum levels in a population of apulian postmenopausal women.
    D'Amore M, Fanelli M, D'Amore S, Fontana A, Minenna G.
    Panminerva Med; 2006 Dec; 48(4):215-21. PubMed ID: 17215793
    [Abstract] [Full Text] [Related]

  • 5. Relationships among serum receptor of nuclear factor-kappaB ligand, osteoprotegerin, high-sensitivity C-reactive protein, and bone mineral density in postmenopausal women: osteoimmunity versus osteoinflammatory.
    Nabipour I, Larijani B, Vahdat K, Assadi M, Jafari SM, Ahmadi E, Movahed A, Moradhaseli F, Sanjdideh Z, Obeidi N, Amiri Z.
    Menopause; 2009 Dec; 16(5):950-5. PubMed ID: 19387415
    [Abstract] [Full Text] [Related]

  • 6. Effects of alendronate treatment on serum levels of osteoprotegerin and total receptor activator of nuclear factor kappaB in women with postmenopausal osteoporosis.
    Reyes-García R, Muñoz-Torres M, García DF, Mezquita-Raya P, García Salcedo JA, de Dios Luna J.
    Menopause; 2010 Dec; 17(1):140-4. PubMed ID: 19574937
    [Abstract] [Full Text] [Related]

  • 7. Association between osteoprotegerin (OPG), receptor activator of nuclear factor-kappaB (RANK), and RANK ligand (RANKL) gene polymorphisms and circulating OPG, soluble RANKL levels, and bone mineral density in Korean postmenopausal women.
    Kim JG, Kim JH, Kim JY, Ku SY, Jee BC, Suh CS, Kim SH, Choi YM.
    Menopause; 2007 Dec; 14(5):913-8. PubMed ID: 17667143
    [Abstract] [Full Text] [Related]

  • 8. Role of type I collagen C telopeptide, bone-specific alkaline phosphatase and osteocalcin in the assessment of bone status in postmenopausal women.
    Trento LK, Pietropolli A, Ticconi C, Gravotta E, De Martino MU, Fabbri A, Piccione E.
    J Obstet Gynaecol Res; 2009 Feb; 35(1):152-9. PubMed ID: 19215563
    [Abstract] [Full Text] [Related]

  • 9. Cathepsin K predicts femoral neck bone mineral density change in nonosteoporotic peri- and early postmenopausal women.
    Prezelj J, Ostanek B, Logar DB, Marc J, Hawa G, Kocjan T.
    Menopause; 2008 Feb; 15(2):369-73. PubMed ID: 17882010
    [Abstract] [Full Text] [Related]

  • 10. Serum cathepsin K as a marker of bone metabolism in postmenopausal women treated with alendronate.
    Muñoz-Torres M, Reyes-García R, Mezquita-Raya P, Fernández-García D, Alonso G, Luna Jde D, Ruiz-Requena ME, Escobar-Jiménez F.
    Maturitas; 2009 Nov 20; 64(3):188-92. PubMed ID: 19819089
    [Abstract] [Full Text] [Related]

  • 11. Gene-gene interactions in RANK/RANKL/OPG system influence bone mineral density in postmenopausal women.
    Zupan J, Mencej-Bedrac S, Jurković-Mlakar S, Prezelj J, Marc J.
    J Steroid Biochem Mol Biol; 2010 Jan 20; 118(1-2):102-6. PubMed ID: 19896533
    [Abstract] [Full Text] [Related]

  • 12. Increased formation of 8-iso-prostaglandin F(2alpha) is associated with altered bone metabolism and lower bone mass in hypercholesterolaemic subjects.
    Mangiafico RA, Malaponte G, Pennisi P, Li Volti G, Trovato G, Mangiafico M, Bevelacqua Y, Mazza F, Fiore CE.
    J Intern Med; 2007 Jun 20; 261(6):587-96. PubMed ID: 17547714
    [Abstract] [Full Text] [Related]

  • 13. Higher levels of s-RANKL and osteoprotegerin in children and adolescents with type 1 diabetes mellitus may indicate increased osteoclast signaling and predisposition to lower bone mass: a multivariate cross-sectional analysis.
    Tsentidis C, Gourgiotis D, Kossiva L, Doulgeraki A, Marmarinos A, Galli-Tsinopoulou A, Karavanaki K.
    Osteoporos Int; 2016 Apr 20; 27(4):1631-1643. PubMed ID: 26588909
    [Abstract] [Full Text] [Related]

  • 14. Serum osteoprotegerin and RANKL are not specifically altered in women with postmenopausal osteoporosis treated with teriparatide or risedronate: a randomized, controlled trial.
    Anastasilakis AD, Goulis DG, Polyzos SA, Gerou S, Koukoulis G, Kita M, Avramidis A.
    Horm Metab Res; 2008 Apr 20; 40(4):281-5. PubMed ID: 18275008
    [Abstract] [Full Text] [Related]

  • 15. Response of bone mineral density, inflammatory cytokines, and biochemical bone markers to a 32-week combined loading exercise programme in older men and women.
    Marques EA, Mota J, Viana JL, Tuna D, Figueiredo P, Guimarães JT, Carvalho J.
    Arch Gerontol Geriatr; 2013 Apr 20; 57(2):226-33. PubMed ID: 23623588
    [Abstract] [Full Text] [Related]

  • 16. Changes in the serum levels of osteoprotegerin and soluble receptor activator for nuclear factor kappaB ligand after estrogen-progestogen therapy and their relationships with changes in bone mass in postmenopausal women.
    Kim JG, Kim JH, Lee DO, Kim H, Kim JY, Suh CS, Kim SH, Choi YM.
    Menopause; 2008 Apr 20; 15(2):357-62. PubMed ID: 17925661
    [Abstract] [Full Text] [Related]

  • 17. Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients.
    Dobnig H, Hofbauer LC, Viereck V, Obermayer-Pietsch B, Fahrleitner-Pammer A.
    Osteoporos Int; 2006 Apr 20; 17(5):693-703. PubMed ID: 16435076
    [Abstract] [Full Text] [Related]

  • 18. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin in men with thyroid cancer.
    Mikosch P, Igerc I, Kudlacek S, Woloszczuk W, Gallowitsch HJ, Kresnik E, Stettner H, Grimm G, Lind P, Pietschmann P.
    Eur J Clin Invest; 2006 Aug 20; 36(8):566-73. PubMed ID: 16893379
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.